key: cord-0990370-syyhde5v authors: Fantini, Massimo Caludio; Biancone, Livia; Dragoni, Gabriele; Bezzio, Cristina; Miranda, Agnese; Ribaldone, Davide Giuseppe; Bertani, Angela; Bossa, Fabrizio; Allocca, Mariangela; Buda, Andrea; Mocci, Giammarco; Soriano, Alessandra; Guglielmi, Francesco William; Bertani, Lorenzo; Baccini, Flavia; Loddo, Erica; Privitera, Antonino Carlo; Sartini, Alessandro; Viscido, Angelo; Grossi, Laurino; Casini, Valentina; Gerardi, Viviana; Ascolani, Marta; Di Ruscio, Mirko; Casella, Giovanni; Savarino, Edoardo; Stradella, Davide; Pumpo, Rossella; Cortelezzi, Claudio Camillo; Daperno, Marco; Ciardo, Valeria; Nardone, Olga Maria; Caprioli, Flavio; Vitale, Giovanna; Cappello, Maria; Comberlato, Michele; Alvisi, Patrizia; Festa, Stefano; Campigotto, Michele; Bodini, Giorgia; Balestrieri, Paola; Viola, Anna; Pugliese, Daniela; Armuzzi, Alessandro; Saibeni, Simone; Fiorino, Gionata title: Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey date: 2020-10-08 journal: Inflamm Bowel Dis DOI: 10.1093/ibd/izaa254 sha: cadb6e920ac8cde03551c65dbb56179dd57c944c doc_id: 990370 cord_uid: syyhde5v nan The global spreading of severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection 1-3 has led to a deep reorganization of hospital services affecting inflammatory bowel disease (IBD) units activity worldwide. 4, 5 In many cases, scheduled follow-up visits were cancelled or rescheduled, and access to outpatient clinics was limited to unstable and relapsing patients. A delay in scheduled therapeutic infusions was also reported due to patient's decision or practical issues. 6 Inflammatory bowel disease patients, especially those under biological and immunosuppressive therapies, are believed to have a higher risk to be infected by SARS-CoV-2. Moreover, early treatment of coronavirus disease 2019 (COVID-19) is associated with better outcomes. 7 For these reasons, in a context of strongly limited interactions between IBD patients and IBD care providers, many referral centers started to screen patients for COVID-19-related symptoms by phone or video call interviews. To quantify the capacity of such an approach to identify early stages of COVID-19, the SoCOVID-19 survey, which contained 11 questions related to the activity of remote screening for COVID-19-related symptoms and signs ( Table 1) was sent by the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) to all Italian referral centers for the diagnosis and therapy of IBD. In the period between March 9 and April 14, 2020, 4304 IBD patients in active follow-up at 24 centers throughout Italy, 13 (52%) of which located in the northern Italy-the most affected area in the country-were contacted by phone or video calls. One hundred patients (2.3%) reported symptoms and/or signs compatible with COVID-19, defined as having at least 2 symptoms among fever, cough, dyspnea, anosmia, dysgeusia, and diarrhea. The most common symptom was diarrhea (63.0%), followed by fever (54.0%), cough (53.0%), anosmia (16.0%), dysgeusia (16.0%), and dyspnea (10.0%). Sixty-five (1.2%) patients with suspicious symptoms were judged eligible for SARS-CoV-2 nasopharyngeal swab by the local health care system authorities, and 20 patients (30.8%) resulted positive. Six positive patients (30.0%) were admitted to the hospital, and 2 (10.0%) were transferred to the intensive care unit (ICU). A single patient died from COVID-19 among those initially remotely identified. The remaining 11 patients (55.0%) did not require hospitalization and received domiciliary follow-up ( Fig. 1) . Seventy-seven patients (77.0%) among those with symptoms compatible with COVID-19 were re-interviewed after 2 weeks from the initial contact to check their health status, and 70 patients (90.9%) referred complete resolution of symptoms. During this period, none of the patients autonomously suspended the therapy prescribed by the IBD specialist, although for 24 patients (24.0%), therapy was modified by the contacting center due to suspected symptoms, reflecting the scarce awareness and uncertainty about the risk of concomitant therapies on COVID-19 clinical course at the beginning of the pandemic. Overall, data from our survey indicate that in order to identify one SARS-CoV-2 positive IBD patient, around 215 patients had to be contacted and interviewed. Diarrhea was overreported as compared with the COVID-19 general population, and it was probably related to IBD clinical activity. 8, 9 The proactive remote identification of positive patients did not seemingly change the clinical outcome. Indeed, the rate of hospitalization among the SARS-CoV-2 positive patients was in line with that recently reported in a prospective Italian cohort study of IBD patients affected by COVID-19. 8 Yet, remote screening of IBD patients for suspicious signs and symptoms for COVID-19 might reduce the risk of contact between IBD care providers and potentially infected patients who are candidate to SARS-CoV-2 molecular testing. Italy The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has determined a so far never seen challenge for national health care systems. In-person follow-up visits and diagnostic procedures of patients affected by chronic diseases such as inflammatory bowel fisease (IBD) have been delayed and, in many cases, even canceled. At the same time, IBD patients are considered immunologically fragile subjects due to wide use of immunosuppressants and immunomodulators, and a tight monitoring of early COVID-19-related symptoms is advisable. For this reason, spontaneous activity of telemedicine started in many IBD centers around the world during the lockdown. Here we report results from the SoCOVID-19 survey exploring the detection rate and outcomes of COVID-19 IBD patients remotely identified telemedicine. Clinical and immunological features of severe and moderate coronavirus disease 2019 Clinical features of patients infected with 2019 novel coronavirus in Wuhan Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan experience. J Crohn's Colitis Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: reorganisational response in a high-volume Italian inflammatory bowel disease centre Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19) Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study China Medical Treatment Expert Group for COVID-19. Clinical characteristics of Coronavirus disease 2019 in China How many suspected patients who received SARS-CoV-2 RT-PCR resulted positive? 5How many of the identified positive patients were admitted to the hospital? 6How many of the identified positive patients were admitted to ICU? 7How many of the identified positive patients died? 8How many patients defined as suspected (confirmed and not confirmed) were contacted again after 2 weeks or more from the initial contact? 9How many patients recovered? 10In how many patients with suspicious symptoms or signs the therapy was selfsuspended? 11In how many patients with suspicious symptoms or signs the therapy was modified by the contacting IBD specialist?